Evercore ISI Stays Underperform on NovoCure Ltd. (NVCR), PT $42 Following Data, 'revs from NSCLC won’t start till 2025'
Tweet Send to a Friend
Evercore ISI analyst Vijay Kumar reiterated an Underperform rating and $42.00 price target on NovoCure Ltd. (NASDAQ: NVCR)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
